Leading the Way in Life Science Technologies

GEN Exclusives

More »

Jan. 15, Vol. 25, No. 2

    • Columns

      • Taking a Look at FDA's Critical Path Initiative
      • By the time this article appears in print, the FDA may well have announced its Critical Path Opportunities List, which will be the culmination of the first phase of the Critical Path Initiative announced on March 16, 2004. The document serves as the ... more »
      • The Human Side of Science
      • Are some personalities better suited than others to a scientific career? To provide insight into this issue, BioInformatics (Arlington, VA), a life science market research firm, created the first-ever psychological profile of life science researcher ... more »
      • Building Momentum in Scandinavian Cluster
      • Medicon Valley, the biomedical cluster region of Southern Sweden and Copenhagen, Denmark, recently completed an extensive self-analysis. The good news is that the region continues to be regarded internationally as one of the top clusters in Europe f ... more »
      • High Content Screening Management Options
      • Rapid acquisition and analysis of high volumes of data in biological samples had its advent in the early days of the Human Genome Sequencing Project. For higher layers of genetic information (RNA and protein), microarray technology has facilitated t ... more »
      • Microfluidics Technology Goes Mainstream
      • It has taken little more than a decade for microfluidics-based systems to become accepted and integrated into drug discovery by Big Pharma companies such as Merck, J&J, Pfizer, Lilly, Tashio, Amgen, Novartis, Serono, and Aventis. Microfluidics ... more »
      • Panning for Drug Discovery Gold with New Tools
      • Comparing lab automation in drug discovery to the tools used in the gold rush may not be so far fetched. "At first people panned for gold. Surface mining provided brute force, thus increasing the throughput, but the efficiency wasn't much b ... more »
      • Pharmacogenomic Tests for Breast Cancer
      • Gail Dutton
      • A test just on the market by Genomic Health (www.genomichealth.com) predicts the recurrence risk for individual breast cancer patients and, importantly, which patients may benefit from tamoxifren and which might not. The information, presented at l ... more »

Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »